<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35571990</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2632-2498</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>4</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Season>Jan-Dec</Season>
            </PubDate>
          </JournalIssue>
          <Title>Neuro-oncology advances</Title>
          <ISOAbbreviation>Neurooncol Adv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo.</ArticleTitle>
        <Pagination>
          <StartPage>vdac047</StartPage>
          <MedlinePgn>vdac047</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">vdac047</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/noajnl/vdac047</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas with complex molecular and genetic alterations. Powerful tumor suppressors <i>CDKN2A</i> and <i>TP53</i> are commonly disrupted along with <i>NF1</i>, a gene that encodes a negative regulator of Ras. Many additional factors have been implicated in MPNST pathogenesis. A greater understanding of critical drivers of MPNSTs is needed to guide more informed targeted therapies for patients. RABL6A is a newly identified driver of MPNST cell survival and proliferation whose <i>in vivo</i> role in the disease is unknown.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Using CRISPR-Cas9 targeting of <i>Nf1 + Cdkn2a</i> or <i>Nf1 + Tp53</i> in the mouse sciatic nerve to form <i>de novo</i> MPNSTs, we investigated the biological significance of RABL6A in MPNST development. Terminal tumors were evaluated by western blot, qRT-PCR, and immunohistochemistry.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Mice lacking <i>Rabl6</i> displayed slower tumor progression and extended survival relative to wildtype animals in both genetic contexts. YAP oncogenic activity was selectively downregulated in <i>Rabl6</i>-null, <i>Nf1 + Cdkn2a</i> lesions whereas loss of RABL6A caused upregulation of the CDK inhibitor, p27, in all tumors. Paradoxically, both models displayed elevated Myc protein and Ki67 staining in terminal tumors lacking RABL6A. In <i>Nf1 + p53</i> tumors, cellular atypia and polyploidy were evident and increased by RABL6A loss.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">These findings demonstrate that RABL6A is required for optimal progression of NF1 mutant MPNSTs <i>in vivo</i> in both <i>Cdkn2a</i> and <i>p53</i> inactivated settings. However, sustained RABL6A loss may provide selective pressure for unwanted alterations, including increased Myc, cellular atypia, and polyploidy, that ultimately promote a hyper-proliferative tumor phenotype akin to drug-resistant lesions.</AbstractText>
          <CopyrightInformation>© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kohlmeyer</LastName>
            <ForeName>Jordan L</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Medicine Graduate Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Department of Neuroscience and Pharmacology, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaemmer</LastName>
            <ForeName>Courtney A</ForeName>
            <Initials>CA</Initials>
            <AffiliationInfo>
              <Affiliation>The Department of Neuroscience and Pharmacology, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lingo</LastName>
            <ForeName>Joshua J</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Biology Graduate Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Voigt</LastName>
            <ForeName>Ellen</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Biology Graduate Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medical Scientist Training Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leidinger</LastName>
            <ForeName>Mariah R</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>The Department of Pathology, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McGivney</LastName>
            <ForeName>Gavin R</ForeName>
            <Initials>GR</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Biology Graduate Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scherer</LastName>
            <ForeName>Amanda</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>The Department of Internal Medicine, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koppenhafer</LastName>
            <ForeName>Stacia L</ForeName>
            <Initials>SL</Initials>
            <AffiliationInfo>
              <Affiliation>The Department of Pediatrics, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gordon</LastName>
            <ForeName>David J</ForeName>
            <Initials>DJ</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Medicine Graduate Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Biology Graduate Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medical Scientist Training Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Department of Pediatrics, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Breheny</LastName>
            <ForeName>Patrick</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-0650-1119</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biostatistics, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meyerholz</LastName>
            <ForeName>David K</ForeName>
            <Initials>DK</Initials>
            <Identifier Source="ORCID">0000-0003-1552-3253</Identifier>
            <AffiliationInfo>
              <Affiliation>The Department of Pathology, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanas</LastName>
            <ForeName>Munir R</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Medicine Graduate Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Biology Graduate Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Department of Pathology, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dodd</LastName>
            <ForeName>Rebecca D</ForeName>
            <Initials>RD</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Medicine Graduate Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Biology Graduate Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medical Scientist Training Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Department of Internal Medicine, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quelle</LastName>
            <ForeName>Dawn E</ForeName>
            <Initials>DE</Initials>
            <Identifier Source="ORCID">0000-0001-8776-0122</Identifier>
            <AffiliationInfo>
              <Affiliation>Molecular Medicine Graduate Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Biology Graduate Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Department of Neuroscience and Pharmacology, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medical Scientist Training Program, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Department of Pathology, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurooncol Adv</MedlineTA>
        <NlmUniqueID>101755003</NlmUniqueID>
        <ISSNLinking>2632-2498</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">MPNST</Keyword>
        <Keyword MajorTopicYN="N">Myc</Keyword>
        <Keyword MajorTopicYN="N">NF1</Keyword>
        <Keyword MajorTopicYN="N">RABL6A</Keyword>
        <Keyword MajorTopicYN="N">YAP</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>4</Hour>
          <Minute>6</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35571990</ArticleId>
        <ArticleId IdType="pmc">PMC9092646</ArticleId>
        <ArticleId IdType="doi">10.1093/noajnl/vdac047</ArticleId>
        <ArticleId IdType="pii">vdac047</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Prudner BC, Ball T, Rathore R, Hirbe AC. Diagnosis and management of malignant peripheral nerve sheath tumors: current practice and future perspectives. Neurooncol Adv 2020;2(Suppl 1):i40–i49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7317062</ArticleId>
            <ArticleId IdType="pubmed">32642731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pemov A, Li H, Presley W, Wallace MR, Miller DT. Genetics of human malignant peripheral nerve sheath tumors. Neurooncol Adv 2020;2(Suppl 1):i50–i61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7317054</ArticleId>
            <ArticleId IdType="pubmed">32642732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miettinen MM, Antonescu CR, Fletcher CDM, et al. . 
Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol. 2017;67:1–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5628119</ArticleId>
            <ArticleId IdType="pubmed">28551330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Williams KB, Largaespada DA. New model systems and the development of targeted therapies for the treatment of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Genes (Basel)  2020;11(5):477. doi:10.3390/genes11050477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/genes11050477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cichowski K, Shih TS, Schmitt E, et al. . 
Mouse models of tumor development in neurofibromatosis type 1. Science 1999;286(5447):2172–2176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10591652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vogel KS, Klesse LJ, Velasco-Miguel S, et al. . 
Mouse tumor model for neurofibromatosis type 1. Science 1999;286(5447):2176–2179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3079436</ArticleId>
            <ArticleId IdType="pubmed">10591653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gregorian C, Nakashima J, Dry SM, et al. . 
PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci USA. 2009;106(46):19479–19484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2765459</ArticleId>
            <ArticleId IdType="pubmed">19846776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Keng VW, Watson AL, Rahrmann EP, et al. . 
Conditional inactivation of Pten with EGFR overexpression in schwann cells models sporadic MPNST. Sarcoma 2012;2012:620834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3539440</ArticleId>
            <ArticleId IdType="pubmed">23319880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dodd RD, Mito JK, Eward WC, et al. . 
NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. Mol Cancer Ther. 2013;12(9):1906–1917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3825462</ArticleId>
            <ArticleId IdType="pubmed">23858101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rahrmann EP, Watson AL, Keng VW, et al. . 
Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet. 2013;45(7):756–766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3695033</ArticleId>
            <ArticleId IdType="pubmed">23685747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huang J, Chen M, Whitley MJ, et al. . 
Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma. Nat Commun. 2017;8:15999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5508130</ArticleId>
            <ArticleId IdType="pubmed">28691711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kohlmeyer JL, Gordon DJ, Tanas MR, et al. . 
CDKs in sarcoma: mediators of disease and emerging therapeutic targets. Int J Mol Sci.  2020;21(8):3018. doi:10.3390/ijms21083018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21083018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Muniz VP, Askeland RW, Zhang X, et al. . 
RABL6A promotes oxaliplatin resistance in tumor cells and is a new marker of survival for resected pancreatic ductal adenocarcinoma patients. Genes Cancer. 2013;4(7-8):273–284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3807645</ArticleId>
            <ArticleId IdType="pubmed">24167655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Montalbano J, Jin W, Sheikh MS, Huang Y. RBEL1 is a novel gene that encodes a nucleocytoplasmic Ras superfamily GTP-binding protein and is overexpressed in breast cancer. J Biol Chem. 2007;282(52):37640–37649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17962191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li YY, Fu S, Wang XP, et al. . 
Down-regulation of c9orf86 in human breast cancer cells inhibits cell proliferation, invasion and tumor growth and correlates with survival of breast cancer patients. PLoS One. 2013;8(8):e71764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3743754</ArticleId>
            <ArticleId IdType="pubmed">23977139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Peng GL, Tao YL, Wu QN, Zhang Y, He JX. Positive expression of protein chromosome 9 open reading frame 86 (C9orf86) correlated with poor prognosis in non-small cell lung cancer patients. J Thorac Dis. 2016;8(7):1449–1459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4958800</ArticleId>
            <ArticleId IdType="pubmed">27499931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yoshimura K, Osman M, Inoue Y, Suda T, Sugimura HA. novel prognostic marker of non-small cell lung cancer: chromosome 9 open reading frame 86 (C9orf86). J Thorac Dis. 2016;8(9):2284–2286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5059359</ArticleId>
            <ArticleId IdType="pubmed">27746955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Desai C, Thomason J, Kohlmeyer JL, et al. . 
Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas. Oncotarget. 2021;12(8):740–755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8057271</ArticleId>
            <ArticleId IdType="pubmed">33889298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kohlmeyer JL, Kaemmer CA, Pulliam C, et al. . 
RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4/6 inhibitors. Clin Cancer Res. 2020;26(12):2997–3011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7299809</ArticleId>
            <ArticleId IdType="pubmed">32086342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Scherer A, Stephens VR, McGivney GR, et al. . 
Distinct tumor microenvironments are a defining feature of strain-specific CRISPR/Cas9-Induced MPNSTs. Genes (Basel)  2020;11(5):583. doi:10.3390/genes11050583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/genes11050583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maharjan CK, Umesalma S, Kaemmer CA, et al. . 
RABL6A promotes pancreatic neuroendocrine tumor angiogenesis and progression in vivo. Biomedicines 2021;9(6):633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8228095</ArticleId>
            <ArticleId IdType="pubmed">34199469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Desai C, Thomason J, Kohlmeyer JL, et al. . 
Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcoma. Oncotarget. 2021;12(8):740–755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8057271</ArticleId>
            <ArticleId IdType="pubmed">33889298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tompkins V, Hagen J, Zediak VP, Quelle DE. Identification of novel ARF binding proteins by two-hybrid screening. Cell Cycle. 2006;5(6):641–646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16582619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang X, Hagen J, Muniz VP, et al. . 
RABL6A, a novel RAB-like protein, controls centrosome amplification and chromosome instability in primary fibroblasts. PLoS One. 2013;8(11):e80228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3839920</ArticleId>
            <ArticleId IdType="pubmed">24282525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
di Tommaso A, Hagen J, Tompkins V, et al. . 
Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities. Exp Cell Res. 2009;315(7):1326–1335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2665200</ArticleId>
            <ArticleId IdType="pubmed">19331830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Magallon-Lorenz M, Fernandez-Rodriguez J, Terribas E, et al. . 
Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiation. Hum Genet. 2021;140(8):1241–1252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34059954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer. 2006;6(9):663–673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16915296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Quelle DE, Nteeba J, Darbro BW. The INK4a/ARF Locus. In: Bradshaw R, Stahl P, eds, Encyclopedia of Cell Biology. Waltham, MA: Academic Press; 2016:447–457.</Citation>
        </Reference>
        <Reference>
          <Citation>
Lui K, An J, Montalbano J, et al. . 
Negative regulation of p53 by Ras superfamily protein RBEL1A. J Cell Sci. 2013;126(Pt 11):2436–2445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3679486</ArticleId>
            <ArticleId IdType="pubmed">23572512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wu LMN, Deng Y, Wang J, et al. . 
Programming of Schwann Cells by Lats1/2-TAZ/YAP signaling drives malignant peripheral nerve sheath tumorigenesis. Cancer Cell 2018;33(2):292–308.e7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5813693</ArticleId>
            <ArticleId IdType="pubmed">29438698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Velez-Reyes GL, Koes N, Ryu JH, et al. . 
Transposon mutagenesis-guided CRISPR/Cas9 screening strongly implicates dysregulation of Hippo/YAP signaling in malignant peripheral nerve sheath tumor development. Cancers (Basel).  2021;13(7):1584. doi:10.3390/cancers13071584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13071584</ArticleId>
            <ArticleId IdType="pmc">PMC8038069</ArticleId>
            <ArticleId IdType="pubmed">33808166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hagen J, Muniz VP, Falls KC, et al. . 
RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner. Cancer Res. 2014;74(22):6661–6670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4233153</ArticleId>
            <ArticleId IdType="pubmed">25273089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tang H, Ji F, Sun J, et al. . 
RBEL1 is required for osteosarcoma cell proliferation via inhibiting retinoblastoma 1. Mol Med Rep. 2016;13(2):1275–1280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26676380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Umesalma S, Kaemmer CA, Kohlmeyer JL, et al. . 
RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. J Clin Invest. 2019;129(4):1641–1653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6436899</ArticleId>
            <ArticleId IdType="pubmed">30721156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maharjan CK, Umesalma S, Kaemmer CA, et al. . 
2021. RABL6A promotes pancreatic neuroendocrine tumor angiogenesis and progression in vivo. Biomedicines. 2021;9(6):633. doi:10.3390/biomedicines9060633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biomedicines9060633</ArticleId>
            <ArticleId IdType="pmc">PMC8228095</ArticleId>
            <ArticleId IdType="pubmed">34199469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Song Y, Zhao Y, Deng Z, Zhao R, Huang Q. Stress-induced polyploid giant cancer cells: unique way of formation and non-negligible characteristics. Front Oncol. 2021;11:724781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8435787</ArticleId>
            <ArticleId IdType="pubmed">34527590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Duensing S, Munger K. Centrosomes, genomic instability, and cervical carcinogenesis. Crit Rev Eukaryot Gene Expr. 2003;13(1):9–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12839094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kourea HP, Cordon-Cardo C, Dudas M, Leung D, Woodruff JM. Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol. 1999;155(6):1885–1891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1866917</ArticleId>
            <ArticleId IdType="pubmed">10595919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brekke HR, Kolberg M, Skotheim RI, et al. . 
Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro Oncol. 2009;11(5):514–528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2765341</ArticleId>
            <ArticleId IdType="pubmed">19182148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zanconato F, Cordenonsi M, Piccolo S. YAP and TAZ: a signalling hub of the tumour microenvironment. Nat Rev Cancer. 2019;19(8):454–464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31270418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bretones G, Delgado MD, Leon J. Myc and cell cycle control. Biochim Biophys Acta. 2015;1849(5):506–516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24704206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fernandez LA, Squatrito M, Northcott P, et al. . 
Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene 2012;31(15):1923–1937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3583298</ArticleId>
            <ArticleId IdType="pubmed">21874045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mazhar S, Taylor SE, Sangodkar J, Narla G. Targeting PP2A in cancer: combination therapies. Biochim Biophys Acta Mol Cell Res. 2019;1866(1):51–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6436821</ArticleId>
            <ArticleId IdType="pubmed">30401535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
McCubrey JA, Steelman LS, Chappell WH, et al. . 
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 2012;3(9):954–987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3660063</ArticleId>
            <ArticleId IdType="pubmed">23006971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kuzyk A, Mai S. c-MYC-induced genomic instability. Cold Spring Harb Perspect Med. 2014;4(4):a014373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3968784</ArticleId>
            <ArticleId IdType="pubmed">24692190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1614522</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
